Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,082,751
  • Shares Outstanding, K 92,622
  • Annual Sales, $ 176,320 K
  • Annual Income, $ -189,290 K
  • 60-Month Beta 0.93
  • Price/Sales 6.16
  • Price/Cash Flow N/A
  • Price/Book 4.08
Trade FGEN with:

Options Overview

Details
  • Implied Volatility 69.90%
  • Historical Volatility 38.85%
  • IV Percentile 32%
  • IV Rank 17.83%
  • IV High 153.48% on 07/07/21
  • IV Low 51.76% on 08/23/21
  • Put/Call Vol Ratio 0.36
  • Today's Volume 91
  • Volume Avg (30-Day) 389
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 1,536
  • Open Int (30-Day) 6,162

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.05
  • Number of Estimates 8
  • High Estimate 0.73
  • Low Estimate -1.00
  • Prior Year 0.35
  • Growth Rate Est. (year over year) -114.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.08 +1.53%
on 09/20/21
12.66 -11.13%
on 09/01/21
-0.86 (-7.10%)
since 08/20/21
3-Month
11.08 +1.53%
on 09/20/21
30.12 -62.66%
on 06/25/21
-15.71 (-58.27%)
since 06/18/21
52-Week
11.08 +1.53%
on 09/20/21
57.21 -80.34%
on 02/12/21
-33.26 (-74.72%)
since 09/18/20

Most Recent Stories

More News
FibroGen (FGEN) Meets Main Goal in Chemo-Induced Anemia Study

FibroGen (FGEN) announces positive top-line data from the study of its investigational candidate roxadustat, which is being evaluated to treat chemotherapy-induced anemia.

REGN : 646.07 (-0.89%)
AZN : 58.01 (+4.41%)
VRTX : 186.53 (-0.94%)
FGEN : 11.38 (-2.65%)
FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

FibroGen, Inc. (NASDAQ: FGEN) today announced positive topline results from WHITNEY, the Company's Phase 2 clinical study of roxadustat, a first-in-class oral small molecule hypoxia-inducible factor prolyl...

FGEN : 11.38 (-2.65%)
Fibrogen (FGEN)/Astellas Get EU Nod for Roxadustat for Anemia

Roxadustat, FibroGen (FGEN) and Astellas' candidate for symptomatic anemia of chronic kidney disease, secures EU approval. The drug is to be sold in Europe under the brand name Evrenzo.

AZN : 58.01 (+4.41%)
IRWD : 12.18 (-1.38%)
MRNA : 423.64 (-1.49%)
FGEN : 11.38 (-2.65%)
Pre-Market Brief: Stocks Set to Open Lower on Threat of More Chinese Restrictions

Morning Markets Sep S&P 500 futures this morning are down -0.34% and are only modestly above Thursday’s 4-week low. Stocks are lower on concern about faltering economic growth from the spread of the...

MRNA : 423.64 (-1.49%)
NTES : 80.18 (-3.26%)
PDD : 94.47 (-6.21%)
BILI : 69.97 (-6.00%)
BIDU : 154.03 (-5.04%)
JD : 73.68 (-5.16%)
BLND : 15.13 (-6.02%)
ROST : 112.26 (-2.06%)
DE : 339.00 (-2.89%)
FL : 48.99 (-1.29%)
FGEN : 11.38 (-2.65%)
Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

Aug. 19, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced...

ALPMY : 16.9025 (-1.04%)
FGEN : 11.38 (-2.65%)
FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer

FibroGen, Inc. (NASDAQ: FGEN) announced the retirement of Pat Cotroneo, Chief Financial Officer, and the appointment of Juan Graham in that role. Pat will continue as Chief Financial Officer through September...

FGEN : 11.38 (-2.65%)
FibroGen's (FGEN) Drug for Anemia of CKD Gets CRL From FDA

NDA for roxadustat, FibroGen's (FGEN) candidate for anemia of chronic kidney disease, fails to secure approval as the FDA requests additional clinical data on the drug. The stock declines resultantly.

AZN : 58.01 (+4.41%)
IRWD : 12.18 (-1.38%)
RGEN : 309.47 (+0.84%)
FGEN : 11.38 (-2.65%)
FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease

FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for roxadustat for the treatment...

FGEN : 11.38 (-2.65%)
FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of -202.08% and -68.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

FGEN : 11.38 (-2.65%)
FibroGen Reports Second Quarter 2021 Financial Results

? Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis.

FGEN : 11.38 (-2.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development...

See More

Key Turning Points

3rd Resistance Point 12.30
2nd Resistance Point 12.08
1st Resistance Point 11.88
Last Price 11.38
1st Support Level 11.46
2nd Support Level 11.24
3rd Support Level 11.04

See More

52-Week High 57.21
Fibonacci 61.8% 39.59
Fibonacci 50% 34.14
Fibonacci 38.2% 28.70
Last Price 11.38
52-Week Low 11.08

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar